Journal of Molecular Modeling

, Volume 17, Issue 3, pp 587–592 | Cite as

Molecular dynamics simulation of oseltamivir resistance in neuraminidase of avian influenza H5N1 virus

  • Mao Shu
  • Zhihua Lin
  • Yunru Zhang
  • Yuqian Wu
  • Hu Mei
  • Yongjun Jiang
Original Paper


The outbreak of avian influenza virus H5N1 has raised a global concern because of its high virulence and mutation rate. Although two classes of antiviral drugs, M2 ion channel protein inhibitors and neuraminidase inhibitors, are expected to be important in controlling the early stages of a potential pandemic. Different strains of influenza viruses have differing degrees of resistance against the antivirals. In order to analyze the detailed information on the viral resistance, molecular dynamics simulations were carried out for the neuraminidase (NA) complex with oseltamivir. The carboxylate of Glu276 of H252Y NA faces toward the O-ethyl-propyl group of oesltamivir, Glu276 of wild-type NA adopts a conformation pointing away from the oesltamivir. τ2 and τ3 torsional angles fluctuation of the oesltamivir are relatively high for the H252Y mutant NA complex. In addition, there are fewer hydrogen bonds between the oesltamivir and H252Y mutation NA. The results show that H252Y mutation NA has high resistance against the drug.


Influenza virus Molecular dynamics simulations Neuraminidase Oseltamivir 



This study was supported by the National Natural Science Foundation of China (No. 60873103), and supported by the Key Project of Natural Science Foundation of China (No. 30830090), and supported by Program for New Century Excellent Talents in University (No.NCET-06-0780), and supported by Visitorg Scholar Foundation of Key Laboratory of Biorheological Science and Technology (No. 2009BST03).


  1. 1.
    Enserink M (2005) Avian influenza: pandemic influenza: global update. Science 309:370–371CrossRefGoogle Scholar
  2. 2.
    de Jong MD, Hien TT (2006) Avian influenza A (H5N1). J Clin Virol 35:2–13CrossRefGoogle Scholar
  3. 3.
    Colman PM (1994) Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci 3:1687–1696CrossRefGoogle Scholar
  4. 4.
    Matrosovich MN, Matrosovich TY, Gray T et al (2004) Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 78:12665–12667CrossRefGoogle Scholar
  5. 5.
    Douglas RG Jr (1990) Prophylaxis and treatment of influenza. N Engl J Med 322:443–450CrossRefGoogle Scholar
  6. 6.
    Wintermeyer SM, Nahata MC (1995) Rimantadine: a clinical perspective. Ann Pharmacother 29:299–310Google Scholar
  7. 7.
    Pinto LH, Holsinger LJ, Lamb RA (1992) Influenza virus M2 protein has ion channel activity. Cell 69:517–528CrossRefGoogle Scholar
  8. 8.
    Hay AJ et al (1993) In: Hannoun CE (ed) Options for the control of influenza virus II. Excerpta Medica, Amsterdam, pp 281–288Google Scholar
  9. 9.
    Jefferson T, Demicheli V, Rivetti D et al (2006) Antivirals for influenza in healthy adults: systematic review. Lancet 367:303–313CrossRefGoogle Scholar
  10. 10.
    Gubareva LV, Kaiser L, Matrosovich MN et al (2001) Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 183:523–531CrossRefGoogle Scholar
  11. 11.
    McKimm-Breschkin JL (2000) Resistance of influenza viruses to neuraminidase inhibitors—a review. Antiviral Res 47:1–17CrossRefGoogle Scholar
  12. 12.
    Moscona A (2005) Oseltamivir resistance-disabling our influenza defenses. N Engl J Med 353:2633–2636CrossRefGoogle Scholar
  13. 13.
    Ferraris O, Lina B (2008) Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol 41:13–19CrossRefGoogle Scholar
  14. 14.
    Adcock SA, McCammon JA (2006) Molecular dynamics: survey of methods for simulating the activity of proteins. Chem Rev 106:1589–1615CrossRefGoogle Scholar
  15. 15.
    van Gusteren WF, Bakowies D, Baron R et al (2006) Biomolecular modeling: goals, problems, perspectives. Angew Chem Int Ed Eng 45:4064–4092CrossRefGoogle Scholar
  16. 16.
    Ravna AW, Sylte I, Dahl SG (2009) Structure and localisation of drug binding sites on neurotransmitter transporters. J Mol Model 15:1155–1164CrossRefGoogle Scholar
  17. 17.
    Masukawa KM, Kollman PA, Kuntz ID (2003) Investigation of Neuraminidase Substrate Recognition Using Molecular Dynamics and Free Energy Calculations. J Med Chem 46:5628–5637CrossRefGoogle Scholar
  18. 18.
    Malaisree M, Rungrotmongkol T, Decha P et al (2008) Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1. Proteins 17:1908–1918CrossRefGoogle Scholar
  19. 19.
    Malaisree M, Rungrotmongkol T, Nunthaboot N et al (2009) Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation. Amino Acids 37:725–732CrossRefGoogle Scholar
  20. 20.
    Udommaneethanakit T, Rungrotmongkol T, Bren U et al (2009) Dynamic behavior of avian influenza a virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues. J Chem Inf Model 49:2323–2332CrossRefGoogle Scholar
  21. 21.
    Amaro RE, Minh DD, Cheng LS et al (2007) Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design. J Am Chem Soc 129:7764–7765CrossRefGoogle Scholar
  22. 22.
    Landon MR, Amaro RE, Baron R et al (2008) Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble. Chem Biol Drug Des 71:106–116CrossRefGoogle Scholar
  23. 23.
    Rameix-Welti MA, Agou F, Buchy P et al (2006) Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrob Agents Chemother 50:3809–3815CrossRefGoogle Scholar
  24. 24.
    Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG (2007) Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 51:1414–1424CrossRefGoogle Scholar
  25. 25.
    McKimm-Breschkin JL, Selleck PW, Usman TB et al (2007) Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerging Infectious Diseases 13:1354–1357Google Scholar
  26. 26.
    Russell RJ, Haire LF, Stevens DJ et al (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443:45–49CrossRefGoogle Scholar
  27. 27.
    Frisch MJ, Trucks GW, Schlegel HB et al (1998) Gaussian98, Revision A.7. Gaussian Inc, Pittsburgh, PAGoogle Scholar
  28. 28.
    Bayly C, Cieplak P, Cornell W et al (1993) A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges—the RESP model. J Phys Chem 97:10269–10280CrossRefGoogle Scholar
  29. 29.
    Wang J, Wang W, Kollman PA et al (2006) Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model 25(2):247–260CrossRefGoogle Scholar
  30. 30.
    Jorgensen WL, Chandrasekhar J, Madura J et al (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79:926–935CrossRefGoogle Scholar
  31. 31.
    Duan Y, Wu C, Chowdhury S, Lee MC et al (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 24:1999–2012CrossRefGoogle Scholar
  32. 32.
    Lee MC, Duan Y (2004) Distinguish protein decoys using a scoring function based on AMBER force field, short molecular dynamics simulations and the generalized born solvent model. Proteins 55(3):620–634CrossRefGoogle Scholar
  33. 33.
    Wang J, Wolf RM, Caldwell JW et al (2004) Development and testing of a general Amber force field. J Comput Chem 25:1157–1174CrossRefGoogle Scholar
  34. 34.
    Darden T, York D, Pedersen L (1993) Particle mesh Ewald—an Nlog(N) method for Ewald sums in large systems. J Chem Phy 98:10089–10092CrossRefGoogle Scholar
  35. 35.
    Ryckaert JP, Ciccotti G, Berendsen HJC (1977) Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 23:327–341CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Mao Shu
    • 1
  • Zhihua Lin
    • 1
  • Yunru Zhang
    • 1
  • Yuqian Wu
    • 2
  • Hu Mei
    • 2
  • Yongjun Jiang
    • 3
  1. 1.College of Pharmacy and BioengineeringChongqing University of TechnologyChongqingPeople’s Republic of China
  2. 2.College of BioengineeringChongqing UniversityChongqingPeople’s Republic of China
  3. 3.Key Laboratory for Molecular Design and Nutrition Engineering of Ningbo City, Ningbo Institute of TechnologyZhejiang UniversityNingboPeople’s Republic of China

Personalised recommendations